気管支・肺ならびに尿路の感染症に対する新しい経口用Cephalosporin剤: Cefaclorの臨床効果の検討

書誌事項

タイトル別名
  • CLINICAL STUDIES WITH CEFACLOR, A NEW ORAL CHPHALOSPORIN, IN RESPIRATORY AND URINARY TRACT INFECTIONS
  • キカンシ ハイ ナラビニ ニョウロ ノ カンセンショウ ニ タイスル アタラシ

この論文をさがす

抄録

Thirteen cases of respiratory tract infections including 8 chronic bronchitis, 3 bronchiectasis, 1 bronchopneumonia and 1 acute bronchitis, caused by H. influenzae, H. parainfluenzae, E. coli Enterobacter, S. pneumoniae and S. hemoliticus were treated respectively with cefaclor 250 mg t. i. d. for seven to fourteen days. Eleven cases showed good response in bacteriological and clinical findings.<BR>Seven cases of urinary tract infections including 6 acute pyelitis and 1 acute cystitis caused by E. coli were treated with cefaclor 250 mg t. i. d. or q. i. d. for three to fourteen days and good response was obtained in all cases.<BR>No side effect or adverse reaction was observed except one case of mild diarrhea.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ